Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06421675 |
| Title | Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE) |
| Acronym | EMBRACE |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Ontario Clinical Oncology Group (OCOG) |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Arnie Charbonneau Cancer Institute | Calgary | Alberta | T2N 4Z6 | Canada | Details | |
| Cross Cancer Institute | Edmonton | Alberta | T6G 1Z2 | Canada | Details | |
| Vancouver Cancer Center | Vancouver | British Columbia | V5Z 1L3 | Canada | Details | |
| Juravinski Cancer Center | Hamilton | Ontario | L8V 1C3 | Canada | Details | |
| Ottawa Hospital | Ottawa | Ontario | K1H 8L6 | Canada | Details |